NeoPhore is a biopharmaceutical company focused on developing novel small molecule immuno-oncology therapeutics targeting components of the MMR pathway to modulate neoantigen creation and diversity across various cancers.

NeoPhore

NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.

Innovate UK

Claris Ventures

Sixth Element Capital

3B Future Health Fund

2invest

Astellas Venture Management

NeoPhore Ltd

NeoPhore Ltd is proud to support #WorldCancerDay to raise awareness and #CloseTheCareGap in access to cancer care.
 
At NeoPhore Ltd, we are targeting the dynamics of cancer #neoantigen evolution through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer #immunotherapies.

To learn more head over to https://www.neophore.com/

#worldcancerday #closethecaregap #cancerawareness 

NeoPhore Ltd is delighted to announce a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. 
 
With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group). This extension brings the total raised in Series B financing to £31.1m (approx. USD $39.5m).

To read the full Press Release please head over to https://lnkd.in/dkFa9kVR

#neophore  #drugdiscovery  #seriesb  

NeoPhore’s Julian Blagg and Philippe Riou will be attending the 7th DDR Inhibitor’s Summit, 30 Jan – 1 Feb in Boston, MA, USA.
 
For its 7th year, this industry-focused meeting returns as the community hotspot for DDR inhibitors. To effectively address your main challenges, the brand new pre-conference biomarker focus day will help you develop dynamic range biomarkers, improve pharmacodynamic studies, and optimize patient stratification for DDR inhibitor combination therapies. 
 
On Thursday 1 February at 11.30am (EST) Julian Blagg, EVP Drug Discovery, & Chair of Scientific Advisory Board, NeoPhore Ltd,  will lead the following session “NP1867: A Chemical Probe for Exploring the Role of DNA Mismatch Repair in Human Disease”
 
To access the latest 3-day agenda, expert speaker faculty, workshop details, panel discussions and networking opportunities that will be available at the 7th DDR Inhibitors Summit, please visit https://ter.li/ez47w6

#ddr #mmr #neophore #NP1867 

NeoPhore’s CEO, Matthew Baker, Ph.D, will be attending the J.P. Morgan 42nd Annual Healthcare Conference, 8-11 January 2024 in San Francisco, CA, USA
 
This conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
 
If you would like to meet with Matthew at the conference to learn about NeoPhore Ltd’s first-in-class #oncology pipeline of DNA mismatch repair inhibitors, please reach out to us directly or, alternatively, click below to send NeoPhore a meeting request in the BIO partnering system.

#neophore #jpm2024 #healthcare 

NeoPhore’s CEO, Matthew Baker, Ph.D, CSO, Martin Drysdale, and EVP Drug Discovery, Julian Blagg, will be attending AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA on 11 - 15 October. This conference attracts scientists from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. 

On Saturday October 14th, NeoPhore will present a first disclosure of NP1867, a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2. We will show, for the first time, that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples. The poster presentation will be during Session C (C086), 12:30 pm-4:00 pm Level 2, Exhibit Hall D.

Should you wish to receive a pdf of the poster after the conference, please go to https://lnkd.in/eGsNF-EP

#Targets23 #MMR #neophore #aacr #drugdiscovery 

COM:NEOPHORE

NeoPhore

Financials Not Available